A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Exclusion Criteria

• •All Cohorts
• •1. "Yes" responses for any of the following items on the C-SSRS (within the past 6 months):
• •* Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan)
• •* Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) "Yes" responses for any of the following items on the C-SSRS (within past 2 years):
• •* Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior). Serious risk of suicide in the opinion of the investigator is also exclusionary.
• •2. Diagnosis of moderate to severe substance or alcohol-use disorder (excluding nicotine or caffeine) as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria within 12 months prior to signing the ICF.
• •3. Positive drug screen or a positive test for alcohol at Screening or Baseline Visits.
• •4. Any of the following clinical laboratory test results at the Screening Visit (as assessed by the central laboratory) and at Check-in (Day -1; as assessed by the local laboratory), and confirmed by a single repeat measurement, if deemed necessary:
• •* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.0 × upper limit normal (ULN)
• •* Total bilirubin \>1.5 × ULN. If Gilbert's syndrome is suspected, total bilirubin \>1.5 × ULN is acceptable if the conjugated or direct bilirubin fraction is \<20% of total bilirubin.
• •Cohorts 1 to 5 (Part A)
• •1. Current or past history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus), malignancy (except for basal cell carcinoma of the skin and cervical carcinoma in situ, at the discretion of the investigator), hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
• •2. Current or past history of significant cardiovascular disease.
• •3. Estimated glomerular filtration rate \<60 milliliters per minute (mL/min)/1.73 m\^2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) equation at the Screening Visit or Check-in (Day -1).
• •Cohort 6 (Part B)
• •1. Has either of the following:
• •* History of major depressive episode with psychotic features during the 12 months prior to signing the ICF
• •* History of a diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder
• •2. Has evidence of a clinically relevant neurological disorder other than possible or probable Alzheimer's disease such as, but not limited to, the following:
• •* History of ischemic stroke within 12 months prior to signing the ICF or any evidence of hemorrhagic stroke
• •* History of cerebral amyloid angiopathy, epilepsy, or central nervous system neoplasm
• •3. Estimated glomerular filtration rate \<60 mL/min/1.73 m2, as calculated using the CKD-EPI 2021 equation the Screening Visit.